The Latest Breaking News from Catalyst

Catalyst Biosciences Inc (NASDAQ:CBIO) has agreed to sell its portfolio of protease medicines that regulate complement to Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for $60 million. "This sale is part of the ongoing strategic process that we announced in February to explore alternatives and create value for shareholders. We have significantly reduced our cash burn and continue…

Catalyst Biosciences Inc (NASDAQ: CBIO) shares are trading higher by 180.26% at $1.06 after the company announced it sold its complement portfolio for $60 million.

For as little as A$1 a tin, canned tuna is an excellent, affordable source of protein, polyunsaturated fats and other nutrients. A tin of tuna is significantly cheaper than many types of fresh meat or fish.

Piper Sandler raised the price target marginally on Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) to $8.75 from $8.00, with an Overweight rating unchanged.  Catalyst expects FY22 revenue of $195 million - $205 million, driven by transitioning ~125 patients previously on Ruzurgi onto Firdapse, analyst Joseph Catanzaro writes in a research note.  Wall Street's estimate for sales…

Fashion mavens Olivia von Halle and Daisy Hoppen are among a glossy posse of Kensington residents fighting developers felling trees in the leafy west London suburb. Samuel Fishwick reports

Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) anticipates